Specifically, Catalent's commercial cell therapy manufacturing facility in Princeton, New Jersey, will support manufacturing ...

Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic collaboration with Galapagos NV (Euronext & NASDAQ: GLPG), a ...

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

For the fourth quarter, the Aristotle Small/Mid Cap Equity Composite generated a total return of -0.45% net of fees, ...

Investment analysts at StockNews.com began coverage on shares of Catalent (NYSE:CTLT – Get Free Report) in a report released on Monday. The firm set a “hold” rating on the stock. Other equities ...

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 ...

TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on NVO stock, giving a Buy rating on January 13.Stay Ahead of the ...

Will further expand Galapagos’ manufacturing network in the U.S. for improved patient experience.

Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...

Lennox International will join the S&P 500 before the open on Dec. 23, replacing Catalent, with the contract drug manufacturer acquired by Novo Nordisk. Lennox stock rose modestly late.

Novo Holdings, the controlling shareholder of Novo Nordisk , on Wednesday sealed its $16.5 billion deal for Catalent , as the Danish drugmaker looks to boost supplies of its widely popular weight ...